Feb 22 (Reuters) - Moderna Inc said on Wednesday its experimental mRNA skin cancer vaccine in combination with Merck & Co Inc blockbuster drug Keytruda has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA). (Reporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli)